These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 32088745

  • 21. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
    Schiller G, Lee M, Paquette R, Sawyers C, Khoubian F, Territo M.
    Leuk Lymphoma; 1999 May; 33(5-6):475-84. PubMed ID: 10342575
    [Abstract] [Full Text] [Related]

  • 22. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
    Gill H, Yim R, Pang HH, Lee P, Chan TSY, Hwang YY, Leung GMK, Ip HW, Leung RYY, Yip SF, Kho B, Lee HKK, Mak V, Chan CC, Lau JSM, Lau CK, Lin SY, Wong RSM, Li W, Ma ESK, Li J, Panagiotou G, Sim JPY, Lie AKW, Kwong YL.
    Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
    [Abstract] [Full Text] [Related]

  • 23. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W, Barnett MJ, Hogge DE, Forrest DL, Nevill TJ, Narayanan S, Power MM, Nantel SH, Broady R, Song KW, Toze CL, Mourad YA, Sutherland HJ, Gerrie AS, White J, Sanford DS.
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [Abstract] [Full Text] [Related]

  • 24. Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Zeng Q, Xiang B, Liu Z.
    Ann Hematol; 2022 Aug; 101(8):1711-1718. PubMed ID: 35570208
    [Abstract] [Full Text] [Related]

  • 25. Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.
    Adrianzen Herrera D, Kornblum N, Derman O, Bachier-Rodriguez L, Sica RA, Shastri A, Janakiram M, Verma A, Braunschweig I, Mantzaris I.
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):516-521. PubMed ID: 31227357
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P.
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K, Kennedy G, Mollee P, Marlton P, Morris K.
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [Abstract] [Full Text] [Related]

  • 30. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S, Rahamim E, Sarid N, Rozovski U, Gibstein L, Aviv F, Kirsner I, Naparstek E.
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 32. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 33. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E, Nygren P, Glimelius B, SBU-group. Swedish Council of Technology Assessment in Health Care.
    Acta Oncol; 2001 Aug; 40(2-3):231-52. PubMed ID: 11441935
    [Abstract] [Full Text] [Related]

  • 34. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN, Troitskaia VV, Kliasova GA, Kuz'mina LA, Sokolov AN, Paramonova EV, Galstian GM, Kessel'man SA, Drokov MIu, Vasil'eva VA, Obukhova TN, Kulikov SM, Savchenko VG.
    Ter Arkh; 2014 Aug; 86(7):14-23. PubMed ID: 25314773
    [Abstract] [Full Text] [Related]

  • 35. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T.
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
    Wang LJ, Ding J, Zhu CY, Yang H, Wang HX, Jing Y, Yu L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):19-24. PubMed ID: 26913387
    [Abstract] [Full Text] [Related]

  • 38. Anthracycline dose intensification in acute myeloid leukemia.
    Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.
    N Engl J Med; 2009 Sep 24; 361(13):1249-59. PubMed ID: 19776406
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.